ISTA Plans to File PROLENSA New Drug Application in First Quarter 2012 PROLENSA's Formulation Covered by Pending Patent Applications IRVINE, CA, Oct 13, 2011 (MARKETWIRE via COMTEX) -- ISTA ...
Please provide your email address to receive an email when new articles are posted on . The U.S. Food and Drug Administration approved Bausch + Lomb’s new drug application for bromfenac ophthalmic ...
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced ...
Company announced that the United States Patent and Trademark Office has issued Patent No. 8,129,431 with claims covering PROLENSA(TM) (bromfenac ophthalmic solution), ISTA's once-daily topical ...
In October, ISTA reported statistically significant Phase 3 results for its product candidate, PROLENSA™ (bromfenac ophthalmic solution), which incorporates this proprietary formulation of bromfenac.
New Once-Daily NSAID Indicated for Treatment of Postoperative Inflammation and Reduction of Ocular Pain Following Cataract Surgery PROLENSA provides powerful and rapid resolution of inflammation and ...
PROLENSA (bromfenac) ophthalmic solution The FDA has approved Bausch & Lomb's New Drug Application for Prolensa ophthalmic solution, which treats post-operative inflammation and reduces ocular pain in ...
The United States Patent and Trademark Office (US PTO) has granted Patent No. 8,129,431 to ISTA Pharmaceuticals' once-daily topical non-steroidal anti-inflammatory product Prolensa (bromfenac ...
today announced that the United States Patent and Trademark Office has issued Patent No. 8,129,431 with claims covering PROLENSA™ (bromfenac ophthalmic solution), ISTA's once-daily topical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results